Trial Profile
Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Clarithromycin (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 26 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 15 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2017 Status changed from not yet recruiting to recruiting.